Home General Biotechnology Drug Patent Expirations in September 2012

Drug Patent Expirations in September 2012

Drug Patent Expirations for September 2012

TradenameApplicantGeneric NamePatent NumberPatent Expiration
GEODONPfizer Incziprasidone hydrochloride5,312,925Sep 1, 2012
GEODONPfizerziprasidone hydrochloride5,312,925Sep 1, 2012
BESIVANCEBausch And Lombbesifloxacin hydrochloride5,447,926Sep 5, 2012
ALREXBausch And Lombloteprednol etabonate4,996,335*PEDSep 9, 2012
ZYLETBausch And Lombloteprednol etabonate; tobramycin4,996,335*PEDSep 9, 2012
LOTEMAXBausch And Lombloteprednol etabonate4,996,335*PEDSep 9, 2012
EMENDMerck And Co Incfosaprepitant dimeglumine7,214,692Sep 18, 2012
EMENDMerckaprepitant7,214,692Sep 18, 2012
EXFORGENovartisamlodipine besylate; valsartan5,399,578*PEDSep 21, 2012
DIOVANNovartisvalsartan5,399,578*PEDSep 21, 2012
LATISSEAllerganbimatoprost6,403,649Sep 21, 2012
EXFORGE HCTNovartisamlodipine besylate; hydrochlorothiazide; valsartan5,399,578*PEDSep 21, 2012
DIOVAN HCTNovartishydrochlorothiazide; valsartan5,399,578*PEDSep 21, 2012
LUMIGANAllerganbimatoprost6,403,649Sep 21, 2012
SYMBICORTAstrazenecabudesonide; formoterol fumarate dihydrate6,641,800Sep 23, 2012
DETROL LAPharmacia And Upjohntolterodine tartrate5,382,600*PEDSep 25, 2012
TIKOSYNPfizerdofetilide4,959,366Sep 25, 2012
DETROLPharmacia And Upjohntolterodine tartrate5,382,600*PEDSep 25, 2012
NIMBEX PRESERVATIVE FREEAbbviecisatracurium besylate5,453,510Sep 26, 2012
NIMBEXAbbviecisatracurium besylate5,453,510Sep 26, 2012
REVATIOPfizersildenafil citrate5,250,534*PEDSep 27, 2012
VIAGRAPfizer Irelandsildenafil citrate5,250,534*PEDSep 27, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • Moreā€¦
See the Database Preview and Plan Comparison. Contact Us with any questions.